Loading...

GTBP GT BIOPHARMA INC Delisting Actions 8-K Filing

GT B

GTBP

GT BIOPHARMA INC

(GTBP)

2023 8-K

Show Summary

Summary

Equity Offerings

Equity Offerings

Equity Offerings

Warrant Issuance

Warrant Inducement

First Patient Dosed

Nasdaq Compliance

Clinical Trial Agreement

Management Change

FDA Clearance of IND Applic...

Annual Meeting Vote Results

Management Change

Purchase Agreement and Priv...

Amendment to Settlement and...

Reverse Stock Split

Special Meeting of Stockhol...

IND Application for GTB-3650

Notice of Delisting

Departure and Appointment o...

Purchase Agreement

External Links:

GT Biopharma received a deficiency letter from Nasdaq stating that their stock price has been below the minimum requirement for continued listing, but they have been given 180 days to regain compliance.

AI Assistant

GT BIOPHARMA INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.